Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in Melanoma  by Sharma, Arati et al.
The American Journal of Pathology, Vol. 182, No. 4, April 2013ajp.amjpathol.orgBIOMARKERS, GENOMICS, PROTEOMICS, AND GENE REGULATION
Identiﬁcation of Aurora Kinase B and Wee1-Like Protein
Kinase as Downstream Targets of V600EB-RAF in Melanoma
Arati Sharma,*yz SubbaRao V. Madhunapantula,*yz Raghavendra Gowda,*yz Arthur Berg,x Rogerio I. Neves,*yz{k and
Gavin P. Robertson*yz{k**From the Departments of Pharmacology,* Public Health Sciences,x Surgery,{ Dermatologyk and Pathology,** the Melanoma Center,y and the Melanoma
Therapeutics Program,z Pennsylvania State University College of Medicine, Hershey, PennsylvaniaAccepted for publicationC
P
hDecember 21, 2012.
Address correspondence to
Gavin P. Robertson, Ph.D.,
Department of Pharmacology,
Pennsylvania State University
College of Medicine, 500
University Dr., Hershey,
PA 17033. E-mail:
gprobertson@psu.edu.opyright ª 2013 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2012.12.019BRAF is the most mutated gene in melanoma, with approximately 50% of patients containing V600E
mutant protein. V600EB-RAF can be targeted using pharmacological agents, but resistance develops in
patients by activating other proteins in the signaling pathway. Identifying downstream members in this
signaling cascade is important to design strategies to avoid the development of resistance. Unfortu-
nately, downstream proteins remain to be identiﬁed and therapeutic potential requires validation. A
kinase screen was undertaken to identify downstream targets in the V600EB-RAF signaling cascade.
Involvement of aurora kinase B (AURKB) and Wee1-like protein kinase (WEE1) as downstream proteins in
the V600EB-RAF pathway was validated in xenografted tumors, and mechanisms of action were charac-
terized in size- and time-matched tumors. Levels of only AURKB and WEE1 decreased in melanoma cells,
when V600EB-RAF, mitogen-activated protein kinase 1/2, or extracellular signaleregulated kinase 1/2
protein levels were reduced using siRNA compared with other identiﬁed kinases. AURKB and WEE1 were
expressed in tumors of patients with melanoma at higher levels than observed in normal human mela-
nocytes. Targeting these proteins reduced tumor development by approximately 70%, similar to that
observed when inhibiting V600EB-RAF. Furthermore, protein or activity levels of AURKB and WEE1
decreased in melanoma cells when pharmacological agents targeting upstream V600EB-RAF or mitogen-
activated protein kinase were used to inhibit the V600EB-RAF pathway. Thus, AURKB and WEE1 are
targets and biomarkers of therapeutic efﬁcacy, lying downstream of V600EB-RAF in melanomas.
(Am J Pathol 2013, 182: 1151e1162; http://dx.doi.org/10.1016/j.ajpath.2012.12.019)Supported by NIH grants R01 CA-136667-02 and RO1 CA-1138634-02
(G.P.R.) and RO3 CA-142060-2 (A.S.); and the Melanoma Research
Foundation (S.V.M.).Melanoma remains the most common cause of skin cancere
related deaths worldwide.1 The incidence of melanoma
increases with age, with a 28% probability of disease for
individuals <40 years and a 70% probability for those >60
years.2 Approaches to manage advanced melanoma include
surgery, radiation, immunotherapy, chemotherapy, or combi-
nations of these approaches. Patients in the advanced stages
of this disease have few treatment options for long-term
management of the disease, with average 5-year survival
being 10%.3 Therefore, a better understanding of the genes and
processes regulatingmelanoma that could be used for selection
of therapeutic targets as biomarkers for particular drug efﬁcacy
or prognostic indicators to assist in therapeutic agent selection
and for overcoming resistance to targeted agents is needed.
Kinases play a key role regulating cellular proliferation
and drug resistance development.4 In the mitogen-activatedstigative Pathology.
.protein (MAP) kinase pathway, 50% and 25% of sporadic
melanomas harbor BRAF or NRAS mutations, respectively,
which activate the MAP kinase pathway measured through
the activation of extracellular signaleregulated kinase
(ERK).5 These mutations rarely occur in the same cell, but
both mutations activate pathways to regulate diverse cellular
processes aiding cancer development, with the most prom-
inent being regulation of cellular proliferation.6 The most
frequent BRAF mutation is a valine to glutamic acid
substitution at residue 600 (V600E), which increases basal
kinase activity.7 The most common NRAS mutation is
a glutamine to leucine substitution (Q61L), which impairs
Sharma et alGTP hydrolysis and maintains a constitutively active
protein.8
Pharmacological agents have been developed to inhibit the
activity of various proteins in the deregulated MAP kinase
signaling pathway.9e12 Recent FDA approval of Zelboraf
(vemurafenib; formerly known as PLX4032), is a major
breakthrough for individuals with mutant V600EB-RAF.13e16
Vemurafenib leads to a high response rate in patients, but in
most cases, more invasive resistant disease eventually recurs
by circumventing V600EB-RAF, leading to mortality.13,16,17
Therefore, a better understanding of downstream members
of the V600EB-RAF pathways is needed so that these proteins
could be targeted together with vemurafenib or inhibited after
the development of resistance to more effectively manage
this disease.
To identify novel kinases regulating the proliferative
potential of melanoma cells and then pinpoint those lying
downstream of V600EB-RAF in this signaling cascade,
an siRNA-based screen of a library of 636 kinases was
undertaken. AURKB, Wee1-like protein kinase (WEE1),
glycogen synthase kinase-3a (GSK3A), thiamin pyrophos-
phokinase 1 (TPK1), and B-RAF were identiﬁed as potential
modulators of melanoma cell survival. The aurora kinase
family consists of aurora kinase A (AURKA), aurora kinase B
(AURKB), and aurora kinase C (AURKC).18 Involvement of
AURKA in melanoma development has been reported, but it
is not known whether AURKB and AURKC play roles in
melanoma pathogenesis or development of drug resistance.19
WEE1 is a dual-speciﬁcity protein kinase involved in regu-
lating cell cycle progression by phosphorylating and deacti-
vating cyclin-associated CDKs.20,21 WEE1 currently has no
known role in melanoma development. Two isoforms of GSK-
3, called GSK3A and GSK-3b (GSK3B), have been identiﬁed.
Although GSK3B has been shown to play a role in melanoma
development and drug resistance,22 GSK3A has not been
identiﬁed as a melanoma therapeutic target. The TPK catalyzes
phosphorylation of thiamin to thiamin pyrophosphate and also
has no known role in melanoma development.23
This study shows that AURKB, WEE1, GSK3A, and
TPK1 were all expressed in tumors of patients with mela-
noma at higher levels than observed in normal human
melanocytes. However, only AURKB and WEE1 levels
decreased when V600EB-Raf, mitogen-activated protein
kinase (MEK) 1/2, or ERK1/2 were targeted using siRNA,
demonstrating that these proteins were downstream of
V600EB-RAF in the deregulated MAP kinase signaling
pathway. Subsequent studies conﬁrmed that targeting
AURKB or WEE1 reduced melanoma tumor development
and led to a phenotype similar to that observed when inhib-
iting V600EB-RAF in this deregulated signaling cascade.
Furthermore, AURKB or WEE1 levels decreased when
pharmacological agents inhibiting V600EB-Raf or MEK were
used to target melanoma cells. Thus, AURKB andWEE1 can
be used as downstream therapeutic targets and as biomarkers
of efﬁcacy of agents targeting the V600EB-RAF signaling
cascade in melanomas.1152Materials and Methods
Cell Lines and Culture Conditions
Normal human primary melanocytes FOM 103 (provided by
Dr. Meenhard Herlyn, Wistar Institute, Philadelphia, PA)
were cultured as previously described.24 Human ﬁbroblast
FF2441 cells (provided by the laboratory of Dr. Craig
Myers, Penn State College of Medicine, Hershey, PA),
metastatic melanoma cell lines UACC 903 (provided by
Mark Nelson, University of Arizona, Tucson, AZ), A375M
(CRL-1619; ATCC, Manassas, VA), and 1205 Lu (provided
by Dr. Herlyn) were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM; Life Technologies, Grand Island,
NY), supplemented with 10% fetal bovine serum (FBS;
HyClone, Logan, UT) and 1% GlutaMAX from Gibco (Life
Technologies). Radial (WM35 and WM3211) and vertical
(WM115 and WM278) growth phase melanoma cell lines
(provided by Dr. Herlyn) were maintained in Tu 2%
medium, as previously described.25 Cell lines were main-
tained in a 37C humidiﬁed 5% CO2 atmosphere incubator
and periodically monitored for cell phenotype, genetic
biomarkers, and growth potential in culture and xenografts
in mice to conﬁrm the identity of the individual cell lines.siRNA Screening to Identify Kinases Regulating
Melanoma Cell Proliferation
To identify kinases that regulate the proliferative potential of
melanoma cells, an siRNA screen was undertaken using the
human StealthRNAi collection from Invitrogen (Life Tech-
nologies), containing three independent validated siRNAs for
each of 636 kinase targets. Each plate was supplied with
appropriate positive, negative, and transfection controls,
including one ﬂuorescent siRNA control and scrambled
siRNA controls for low, medium, and high guanine-cytosine
(GC) content. A primary screen was performed by trans-
fecting 100 pmol of pooled siRNA (three individual siRNAs
targeting the same kinase) into 2  104 UACC 903 mela-
noma cells using an Amaxa Nucleofector 96-well shuttle
system, program CM-130, and solution SF (Lonza, Wal-
kersville, MD). After 24 to 48 hours of recovery in 10% FBS
containing culturing media, transfected cells were grown in
serum-free media for an additional 3 days and viable cells
were measured using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS) assay (CellTiter 96 AQueous Cell Prolif-
eration Assay; Promega, Madison, WI). A minimum 20%
decrease in cell viability compared with control-transfected
cells was considered as a positive hit in the primary screen.
siRNA-mediated inhibition of V600EB-Raf served as a posi-
tive control for the screen. The second validation step
involved evaluating individual siRNAs of the pool from the
primary screen. Aminimum of two siRNAs had to inhibit cell
survival to proceed. The next step was to validate growth-
inhibitory effects in two additional melanoma cell lines,ajp.amjpathol.org - The American Journal of Pathology
AURKB and WEE1 Downstream of V600EB-RAF1205 Lu and A375M. A candidate kinase only underwent
further study after two independent siRNAs showed similar
growth-inhibitory effects in three independent melanoma cell
lines.
Western Blot Analysis
Cell lysates were collected and processed for Western blot
analysis, as previously described.9,10,24,26,27 A total of 1 to
1.5  106 melanoma cells were plated in 100-mm culture
dishes, treated 48 hours later with 0.2 to 20mmol/L V600EB-Raf
inhibitor; vemurafenib (ChemieTek, Indianapolis, IN) or 2.5
to 50 mmol/L MEK1/2 inhibitor; and U0126 (Cell Signaling
Technologies, Beverly,MA) for 6 to 48 hours. Protein lysates
were collected for Western blot analysis. Blots were probed
with antibodies, according to manufacturer’s recommenda-
tions. Antibodies used in this study were as follows:
AURKB, cyclin D1, ERK2, B-RAF, and a-enolase (Santa
Cruz Biotechnology, Santa Cruz, CA); phospho-AURKB
(LifeSpan Biosciences, Seattle, WA) and phospho-H3
(Millipore, Billerica,MA); TPK1 (Proteintech, Chicago, IL);
and WEE1, phospho-WEE1, GSK3A, total ERK1/2, total
MEK, phospho-MEK1/2, and phospho-ERK1/2 (Cell
Signaling Technology). Secondary antibodies conjugated
with horseradish peroxidase were obtained from Santa Cruz
Biotechnology. Immunoblots were developed using the
enhanced chemiluminescence detection system (Amersham
Pharmacia Biotech, Piscataway, NJ).
siRNA Protein Knockdown Studies
A total of 100 pmol of siRNA was introduced into 1  106
melanoma cells via nucleofection using an Amaxa Nucleo-
fector with Solution R/programK-17 for UACC 903 and 1205
Lu or Solution R/program A-23 for A375M. Transfection
efﬁciency after nucleofectionwas>90%,with 80% to90%cell
viability. After siRNA transfection, cells were left to recover
for 2 days and replated in 96-well plates to assess viability and
proliferation. For duration of siRNA-mediated protein knock-
down studies in vitro, 1.0  106 UACC 903, 1205 Lu, or
A375M cells were nucleofected with small-interfering (si)
AURKB#1, siAURKB#3, siWEE1#2, siWEE1#3, siRNA
against mutant B-RAF, siMEK1 þMEK2, siERK1 þ ERK2,
siCYCLIN D1, and scrambled siRNA and protein lysates
harvested at day 4 or 2, 4, 6, or 8 days later for Western blot
analysis for siRNA knockdown time course experiments. The
following Duplexed Stealth siRNA (Invitrogen) sequences
were used:AURKB#1, 50-CCAACAUCCUGCGUCUCUA-
CAACUA-30; AURKB#2, 50-GGAUCUGUGGUGCAUUG-
GAGUGCUU-30; AURKB#3, 50-ACUUGUCCUCAUGAG-
CCGCUCCAAU-30; WEE1#1, 50-GGGCAUCCAACAAA-
GUUAUGUUUAA-30; WEE1#2, 50-CCAGAGUAAUAG-
AACAUCUCGACUU-30; WEE1#3, 50-CCUCUUCCGAG-
AAAUGGAGAUCAAU-30; GSK3A#1, 50-CCAAGGCCAA-
GUUGACCAUCCCUAU-30; GSK3A#2, 50-GGAGUUCA-
AGUUCCCUCAGAUUAAA-30; GSK3A#3, 50-CCAGGG-The American Journal of Pathology - ajp.amjpathol.orgAACUAGUCGCCAUCAAGAA-30; TPK1#1, 50-GCUA-
CUAAGGGAUGUGAGCUCAUUU-30; TPK1#2, 50-CCA-
CACUGACUUUACUAGUGCCUU-30; and TPK1#3, 50-UG-
GAACAUUGGUCAGUACUUCCAAU-30. The siRNA
validated and published sequences for Scrambled, V600EB-
RAF, MEK1, MEK2, ERK1, ERK2, and CYCLIN D1
were as previously reported.9
Cell Viability and Proliferation Studies
For experiments using siRNA, 1  106 UACC 903 or 1205
Lu cells were nucleofected with 100 pmol of AURKB#1,
siAURKB#3, siWEE1#2, siWEE1#3, siV600EB-Raf (as a
positive control), scrambled siRNA (as a negative control), or
transfection buffer (as a transfection reagent control). Cells
were allowed to recover for 48 hours in 60-mm culture dishes
and then 5 to 10  103 cells were seeded into 96-well plates.
At 3 and 5 days later, cell viability was measured by MTS
assay (Promega), or cell proliferation using the 5-bromo-20-
deoxyuridine (BrdU) enzyme-linked immunosorbent assay
kit (Roche Applied Sciences, Indianapolis) was measured.
For studies using aurora kinase inhibitor (VX-680; LC
Laboratories, Woburn, MA), viability and inhibitory concen-
tration of 50% (IC50) of UACC 903, 1205 Lu, or A375M
melanoma cells were assessed by MTS assay. Brieﬂy, 5  103
melanomaor humanﬁbroblast (FF2441) cells perwell in 100mL
DMEM containing 10% FBS were grown in a 96-well plate for
24 to 76 hours and treatedwith either control dimethyl sulfoxide
(DMSO) vehicle or increasing concentrations (1 to 100 mmol/L)
of VX-680. Cell viability compared with vehicle controle
treated cells wasmeasured using theMTS assay. IC50 values for
each compound in respective cell lines were estimated from
three independent experiments using GraphPad Prism software
version 4.01 (GraphPad Software Inc., La Jolla, CA).
Cell Cycle Analysis
For cell cycle analysis using siRNA, 1  106 UACC 903,
1205 Lu, and A375M cells were nucleofected, as previously
detailed.27 To determine the effects of aurora kinase inhib-
itor on the cell cycle, UACC 903 cells were treated with
VX-680 for 48 hours at a concentration ranging between 2.5
and 7.5 mmol/L. Cells were trypsinized, centrifuged (500  g,
for 5 minutes), and stained with 1 mL of propidium iodide.
Stained cells were analyzed using the FACScan analyzer
(Becton Dickinson Biosciences, San Jose, CA), and data
were processed using ModFit LT software version 3.3
(Verity Software House, Topsham, ME).
Analysis of Tumors from Patients with Melanoma
Melanoma tumor specimens from human patients (n Z 39)
were randomly selected according to the protocols approvedby
the Institutional Review Board at Pennsylvania State Univer-
sity (Hershey, PA), and the Cooperative Human Tissue
Network (Columbus, OH, and Philadelphia, PA). Informed1153
Sharma et alconsent was provided according to theDeclaration ofHelsinki.
Tissue samples were collected from patients at surgery,
immediately snap frozen in liquid nitrogen, and stored at
80C until protein lysate collection. To collect protein for
Western blot analysis, tumors were pulverized using a mortar
and pestle chilled in liquid nitrogen. Protein lysates were
extracted from tumors, as previously reported,26 and analyzed
by using Western blot analysis to assess levels of AURKB,
WEE1, GSK3A, and TPK1. Protein levels in tumors were
normalized toa-enolase loading control, and relativeAURKB,
WEE1, GSK3A, and TPK1 expression levels were quantiﬁed
using ImageJ software version 1.46r (NIH, Bethesda, MD),
compared with melanocyte control, and graphed with the
beeswarmpackage inR package version 0.1.5 (http://CRAN.R-
project.org/packageZbeeswarm, last accessed February 15,
2013).
Animal Tumorigenicity Assessments Using siRNA
Animal experimentation was performed according to proto-
cols approved by the Institutional Animal Care and Use
Committee at Pennsylvania State University. Tumor kinetics
studies were undertaken on athymic-Foxn1nu nude mice
purchased from Harlan Sprague Dawley (Harlan Laborato-
ries, Indianapolis, IN). A total of 100 pmol of siRNA was
nucleofected into 20  106 cells, and after 48 hours of
recovery, 1  106 cells were fractionated in 0.2 mL of 10%
FBS-DMEM and then injected s.c. above both the left and
right rib cages of 4- to 6-week-old female mice (three to ﬁve
mice per group). Dimensions of developing tumors were
measured on alternate days up to day 17.5, using calipers
(Thomas Scientiﬁc, Swedesboro, NJ) by LxWxD (mm3).
Analysis of AURKB and WEE1 Expression, Cell
Proliferation, and Apoptosis Rates in Time- and Size-
Matched Tumors
To generate tumors of the same size developing at parallel time
points, 1 106 UACC 903 melanoma cells nucleofected with
either control buffer or scrambled siRNA or 10  106 cells
nucleofected with AURKB#1 and AURKB#3, WEE1#2, and
WEE1#3 siRNAs were injected into nude mice. Tumors were
harvested at day 11 tomeasureAURKBandWEE1 expression
and activity usingWestern blot analysis. For analyzing the cell
proliferation index and apoptosis in these tumors, mouse anti-
human Ki-67 from BD Pharmingen (BD Biosciences, San
Diego, CA) and a TUNEL TMR Red Apoptosis kit (Roche,
Mannheim, Germany) were used, respectively, as previously
described.26 The number of Ki-67e and TUNEL-stained cells
were quantiﬁed as the percentage of total cells in tumors. To
quantify AURKB and WEE1 expression by immunohisto-
chemistry (IHC) in formalin-ﬁxed, parafﬁn-embedded tumor
sections, tissue sections were deparafﬁnized and rehydrated in
PBS, after which antigen retrieval was undertaken by incuba-
tion in 0.01 mol/L citrate buffer, pH 6.0, for 20 minutes in
a 95Cwater bath. Slides were cooled for 20minutes, rinsed in1154PBS, and incubated in 3% H2O2 for 10 minutes to quench
endogenous peroxidase activity. Next, sections were blocked
with 1% bovine serum albumin for 30 minutes and incubated
with a 1:50dilutionof anti-AURKB(Abcam,Cambridge,MA)
orWEE1 (Abgent, Inc., San Diego, CA) antibody overnight at
4C. After rinsing in PBS, sections were incubated with bio-
tinylated anti-rabbit IgG (BD Pharmingen) for 1 hour and
treated with peroxidase-labeled streptavidin (BD Pharmingen)
for 30 minutes. Visualization was accomplished using 3, 30-
diaminobenzidine for 5 to 10 minutes (BD Pharmingen), and
nuclei were counterstained with hematoxylin (Dako, Carpen-
taria, CA). The percentage of cells that stained positive for
AURKBandWEE1wasmeasured fromaminimumof three to
ﬁve different tumors (four to ﬁve ﬁelds per tumor). Sections
were imaged using a Nikon Eclipse 600 camera (Nikon, Mel-
ville, NY), photographed at 400 magniﬁcation, and quanti-
ﬁed using Image Processing laboratory imaging software
version 4.0.14 (Scanalytics, Fairfax, VA).
Tumor Studies Using VX-680, Vemurafenib, or U0126
A total of 1.5  106 UACC 903 cells in 0.2 mL of DMEM,
supplemented with 10% FBS, were s.c. injected above both
left and right rib cages of 3- to 4-week-old female athymic
nude-Foxn1nu mice (Harlan Sprague Dawley). Six days later,
when a fully vascularized tumor of 50 to 75 mm3 had formed,
mice were randomly divided into DMSO vehicle control and
experimental groups (three mice per group and two tumors
per mouse) and treated i.p. with 50 or 75 mg/kg body weight
VX-680 on alternate days for 3 to 4 weeks. Twenty-six days
later, tumors were harvested and analyzed by IHC and
Western blot analysis, as previously detailed. vemurafenib or
U0126 was dissolved in 10 mg/kg body weight DMSO and
injected i.p. every day for 6 days. Body weight (in grams) and
dimensions of developing tumors (in mm3) were measured at
drug administration. Tumors were harvested and analyzed for
AURKB and WEE1 expression using IHC, as previously
detailed. Tumors from animals treated with VX-680 were
analyzed for pAURKB, AURKB, and pHistone-3 using
Western blot analysis, as previously mentioned.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
Software version 4.0 and R version 2.15.1 (http://www.r-
project.org). One- or two-way analysis of variance was used
for groupwise comparisons, followed by the Tukey’s or
Bonferroni’s post hoc tests. For comparison between two
groups, the Student’s t-test (two tailed) was used. The two-
sided, one-sample Wilcoxon signed-rank test was used to
analyze tumor samples from patients with melanoma. Results
represent at least two to three independent experiments and are
shown as averages SEM. Results with a P< 0.05 (95% CI)
were considered signiﬁcant. Sample sizes and number of times
experiments were repeated are indicated in the ﬁgure legends.
The level of statistical signiﬁcance is given in the ﬁgures.ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Identiﬁcation of kinases regulating melanoma cell survival.
A: Screen showing identiﬁcation of siAURKB, siWEE1, siGSK3A, siTPK1,
and simutB-RAF as potential key targets in melanoma. A cellular viability
test using MTS was used as the end point assay. B: A secondary validation
step involved measuring inhibitory effects of three individual siRNAs on
UACC 903 cell viability. C: Conﬁrming effect of individual siRNA in
a second melanoma cell line. siRNAs targeting siAURKB, siWEE1, siGSK3A,
and siTPK1 reduced cell viability in multiple cell lines. siRNAs targeting
V600EB-Raf were used as positive controls. Data are representative of
a single experiment done in triplicate (A) and two to three independent
experiments done in triplicate (B and C). Data are represented as means
 SEM percentage of cell viability. *P < 0.05, **P < 0.01.
AURKB and WEE1 Downstream of V600EB-RAFResults
siRNA Screening Identiﬁes Kinases Regulating
Melanoma Cell Survival
To identify kinases that regulate melanoma cell survival, an
siRNA library screen was undertaken using the human Stealth
RNAi collection (Life Technologies). The primary screen
involved transfecting 100 pmol of siRNA pool (three indi-
vidual siRNAs targeting the same kinase) into UACC 903
metastatic melanoma cells using the Amaxa Nucleofector 96-
well shuttle system. The primary screen identiﬁed 33 of 636
kinases (hit rate, 5%). Of the 33 hits, AURKB, WEE1,
GSK3A, TPK1, and B-RAF were identiﬁed among the
possible targets in melanoma development. The identiﬁcation
of B-RAF as one of the targets validated the efﬁcacy of the
primary screen for identifying potentially important proteins
involved in melanoma cell proliferation (Figure 1A). AURKA
and AURKCwere used as controls for related family members
that did not decrease UACC 903 cell survival. The secondary
validation step was to evaluate whether individual siRNAs to
each target would have a similar inhibitory effect to the pooled
siRNA inUACC903 cells (Figure 1B). At least two of the three
siRNAs targeting different regions of each respective mRNA
decreased UACC 903 cell survival and protein expression
(Supplemental Figure S1). Although all three siRNAs
decreased the expression of target protein, only two siRNAs
decreased the proliferative potential (Supplemental Figure S1).
AURKB, WEE1, GSK3A, and TPK1 had at least two siR-
NAs that reduced the proliferative potential of melanoma
cells (Figure 1B). The third validation step involved evalu-
ating the inhibitory efﬁcacy in two additional cell lines, 1205
Lu (Figure 1C) and A375M (data not shown), which showed
similar results to those observed for UACC 903 cells.
siRNAs targeting AURKB, WEE1, GSK3A, and TPK1 had
similar growth-inhibitory effects in all three independently
derived melanoma cell lines.
Expression Levels of AURKB, WEE1, and GSK3A Are
Elevated in Tumors of Patients with Melanoma
To validate involvement of AURKB, WEE1, GSK3A, and
TPK1 in melanoma, protein from tumors of patients with
melanoma (n Z 39) was analyzed for AURKB, WEE1,
GSK3A, and TPK1 expression by usingWestern blot analysis.
Melanoma tumor specimens from human patients were
randomly selected. All of the tumor specimens used were
derived from patients with malignant or metastatic melanoma.
Results were normalized to a-enolase loading control and
compared with normal human melanocyte controls. The fold
changes, relative to melanocytes, were analyzed and graphed
on the log scale for improved visualization and increased
robustness in the analysis. The two-sided, one-sample Wil-
coxon signed-rank test was used to determine whether the
distribution of log fold changes was statistically different from
0 (melanocyteswere normalized to a fold changeof one or a logThe American Journal of Pathology - ajp.amjpathol.orgfold change of zero). A graph shows signiﬁcant up-regulation
of AURKB, WEE1, and GSK3A compared with melano-
cytes. However, TPK1 showed no signiﬁcant (P Z 0.43)
differences compared with melanocyte control (Figure 2A).
Representative Western blot analyses showing expression and
activity of WEE1 and AURKB, compared with melanocyte
control, can be seen (Supplemental Figure S2). Advanced-
stage melanoma cell line UACC 903 was used as a positive
control. Increased expression of these kinases in melanomas
suggested that they might play a potentially important role in1155
Figure 2 Expression and demonstration that AURKB and WEE1, but not
GSK3A or TPK1, lie downstream of V600EB-RAF in the MAP kinaseesignaling
pathway. A: Expression of AURKB, WEE1, GSK3A, and TPK1 in tumor biopsy
specimens from patients with melanoma. Protein isolated from tumors of
patients with melanoma (nZ 39) was analyzed for AURKB, WEE1, GSK3A, and
TPK1 expression by using Western blot analysis. Results were normalized to
a-enolase for equal protein loading and compared with normal human mela-
nocyte controls. Data represent fold changes, relative to melanocytes (mela-
nocytes were normalized to a fold change of one or a log fold change of zero),
and were analyzed and graphed on the log scale. Number of samples for AURKB
(nZ 25, P < 0.0001), WEE1 (nZ 19, PZ 0.0046), GSK3A (nZ 39, PZ
0.0047), andTPK1 (nZ20,PZ 0.43), two-sided one-sampleWilcoxon signed-
rank test. B and C: Decreasing levels of protein expression for each member of
the MAP kinase pathway inhibit AURKB or WEE1 protein or activity levels. siRNA
was introduced into UACC 903 or 1205 Lu cells to reduce protein levels of
V600EB-Raf, MEK1/2, ERK1/2, cyclin D1, and AURKB. The effect on AURKB,
pAURKB, WEE1, GSK3A, or TPK1 protein levels was measured. Compared with
cells treatedwith scrambled siRNA, decreasing protein levels of eachmember of
theMAP kinasepathway led to adecrease inAURKBandWEE1 levels. No changes
were observed in GSK3A or TPK1 levels. a-Enolase served as a control for equal
protein loading. Western blot was reproduced at least two to three times (B).
Figure 3 Expression of AURKB and WEE1 protein in advanced-stage
melanoma cell lines. A and C: Protein lysates collected from normal human
melanocytes, radial (WM35 and WM3211), vertical (WM115 and WM278), and
metastatic (A375M, UACC 903, and 1205 Lu) stage cell lines were subjected to
Western blot (WB) analysis and probed for AURKB and WEE1. B and D: Levels
were normalized to a-enolase loading control and fold increase with respect
to normal human melanocytes quantiﬁed. The bar graph shows fold increase
in expression levels of AURKB andWEE1 inmelanoma cell lines compared with
normal human melanocytes. Western blot data were reproduced at least
twice. NHEM, normal human melanocytes.
Sharma et almelanomadevelopment. The next goalwas to determinewhich
of the kinases lay downstreamof V600EB-RAF in this important
signaling cascade.
AURKB and WEE1 Lie Downstream of V600EB-Raf in the
MAP Kinase Pathway
TheMAPkinasepathway is constitutively active in50%to60%
of melanomas because of a single-base mutation in Braf1156converting T toA at nucleotide 1799,which substitutes a valine
for glutamic acid at codon600 (V600E).7 It is unknownwhether
the V600EB-Raf signaling cascade mediates its proliferative ef-
fects throughAURKB,WEE1,GSK3A, orTPK1 expression or
activity. To determine whether these kinases were regulated by
V600EB-Raf signaling, siRNA-targeting V600EB-Raf, MEK1/2,
or ERK1/2 were nucleofected into UACC 903 or 1205 Lu
melanoma cells, and the effect on expression or activity (ie,
phosphorylated protein levels) of the kinases was examined.
siRNA to cyclin D1 was used to rule out that the kinases are
simply being regulated in a cell cycleedependent manner.
These siRNAs have been previously validated as targeting
MAP kinase proteins in these cell lines.9ajp.amjpathol.org - The American Journal of Pathology
AURKB and WEE1 Downstream of V600EB-RAFsiRNA-mediated knockdown of V600EB-Raf, MEK1/2, or
ERK1/2genes decreased the expression andactivity ofAURKB
andWEE1 in both UACC 903 and 1205 Lu cell lines (Figure 2,
B and C). In contrast, only AURKB protein levels decreased
with the knockdown of cyclin D1, which is an important
downstream transcription factor of the B-Raf/MEK/ERK
cascade.28 No change was observed in GSK3A levels, which is
consistent with its role in regulating apoptosis through the
phosphatidylinositol 3-kinase pathway.29 TPK1 protein levels
were up-regulated on knockdown of V600EB-Raf and MEK1/2
proteins; however, knockdownof neitherERK1/2nor cyclinD1
altered TPK1 levels, indicating that another cascade down-
stream of MEK1/2 protein might be regulating TPK1 protein
levels (Figure 2, B and C). In a well-established cell line tumor
progression model30 (data not shown), all melanoma cell lines
had decreased TPK1 expression compared with the melanocyteFigure 4 siRNA-mediated targeting of AURKB or WEE1 decreased the tumorigenic
was introduced into melanoma cells via nucleofection and protein expression, assesse
scrambled siRNA. Erk2wasused asa control for equal protein loading.Westernblot anal
cells werenucleofectedwith siRNA targetingAURKBorWEE1, and48hours later, viable
were measured on alternate days for 17.5 days. The bar graph presents tumor volume
siRNA#1 and AURKB siRNA#3; and gray bars, WEE1 siRNA#2 and WEE1 siRNA#3. Data w
two tumors per mouse. Each point represents average data obtained from six nude m
variance, followed by the post hoc test. D: IHC staining of xenografted tumors from
crambled controls, or siRNA to AURKB or WEE1. Day 11 tumors were harvested and sta
control tumors. Data were obtained from three to four tumors, with four to ﬁve ﬁelds
The American Journal of Pathology - ajp.amjpathol.orgcontrol; however, no statistically signiﬁcant difference was
observed in patient tumors (Figure 2A). Therefore, the effect
observed in cell culture (Figure 2, B and C) is likely an artifact.
Decreased cyclin D1 levels had no effect on AURKB orWEE1
expression in UACC 903 cells and no effect onWEE1 levels in
1205 Lu cells (Figure 2, B and C). Based on these observations,
subsequent studies focusedonAURKBandWEE1 todetermine
whether these proteins could be used as downstream therapeutic
targets of the V600EB-Raf signaling cascade or as biomarkers of
therapeutic efﬁcacy when using agents targeting this pathway.
Increased Levels of AURKB and WEE1 Protein Are
Observed in Melanoma Cell Lines
Protein activity and expression levels of AURKB and WEE1
in cell lines isolated from the different stages of melanomapotential of melanoma cells. A: A total of 100 pmol of siRNA to AURKB or WEE1
d 2, 4, 6, or 8 days later, and compared with cells treated with control buffer or
ysis datawere reproduced at least twice.B andC: UACC903or1205 Lumelanoma
cells were s.c. injected into left and rightﬂanks of nudemice.Developing tumors
(mm3). Black bars represent buffer and scrambled controls; white bars, AURKB
ere obtained from duplicate experiments with three mice per group, containing
ice. Data represent means SEM. *P < 0.05, **P < 0.01, two-way analysis of
animals injected with UACC 903 melanoma cells transfected with buffer or siS-
ined, and the expression of AURKB or WEE1 was quantiﬁed and compared with
per tumor. Data represent means  SEM. ***P < 0.001, t-test.
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Figure 5 Targeting AURKB or WEE1 reduced melanoma cell survival by
decreasing the proliferative potential of melanoma cells. A and B: Size- and
time-matched tumors from animals injected with UACC 903 melanoma cells
transfected with buffer or siScrambled controls or siRNA to AURKB or WEE1.
Tumor sections were immunostained for Ki-67 (A) or TUNEL (B) for prolif-
eration and apoptosis, respectively. Images were quantiﬁed and plotted as
fold decrease or increase in Ki-67e or TUNEL-positive cells compared with
controls. Data were obtained from three to four tumors, with four to ﬁve
ﬁelds averaged per tumor. C and D: siRNA was introduced in UACC 903 or
1205 Lu melanoma cells and an MTS or BrdU incorporation assay undertaken
after 3 days to measure cell viability or proliferation, respectively. V600EB-RAF
served as a control of a gene decreasing cell viability. Results represent
pooled data from three independent experiments. Data represent means 
SEM. **P < 0.01, ***P < 0.01. ns, not statistically signiﬁcant. An analysis
of variance, followed by a post hoc test, was used.
Sharma et altumor progression were compared with normal human
melanocytes. Compared with the melanocyte control, higher
AURKB levels were observed in all cell lines, except
WM115 cells (Figure 3, A and B). Elevated levels of WEE1
were observed in all cell lines, with the highest occurring in
1205 Lu melanoma cells (Figure 3, C and D). Thus, levels
of AURKB and WEE1 protein expression were increased in
most cell lines compared with melanocytes.
Targeting AURKB or WEE1 Protein Levels in Melanoma
Cells Decreases the Tumorigenic Potential of Melanoma
Cells
To determine the consequence of targeting AURKB orWEE1
in melanoma cells, siRNAs targeting these genes were intro-
duced into UACC 903 and 1205 Lu cells. siRNA efﬁciency
and duration of protein knockdownwere validated by showing
decreased protein levels for 6 to 8 days after transfection
(Figure 4A). Examining duration of in vitro protein knock-
down is essential for evaluation of the effect of siRNA-
mediated targeting of genes for tumor development studies in
animals.9,10,31After siRNA transfection, cellswere injected s.c.
above both the left and right rib cages of 4- to 6-week-old
female nude mice, and dimensions of developing tumors were
measured on alternate days up to day 17.5. For both cell lines,
tumor development was reduced by up to 70% compared with
buffer or scrambled siRNA controls at day 17.5 (Figure 4, B
and C). The IHC analysis showed an approximately 40%
decrease in tumor cell AURKB or WEE1 protein expression
compared with buffer or scrambled siRNA-treated cells 11
days after injection in mice9,10,26,27,31,32 (Figure 4D and
Supplemental Figure S3). Thus, decreasingAURKBorWEE1
protein levels reduced the tumorigenic potential of melanoma
cells. Next, the mechanism of action of targeting either of these
proteins downstream of V600EB-RAF was investigated.
AURKB and WEE1 Inhibition Reduces Melanoma Tumor
Development by Decreasing Cellular Proliferation
To identify the mechanistic basis leading to tumor inhibition
after decreased AURKB orWEE1 protein levels, proliferation
and apoptosis levels in tumors of the same size developing at
day 11 were examined. Formalin-ﬁxed, parafﬁn-embedded
tumor sections were examined by Ki-67 staining to assess
proliferation (Supplemental Figure S4A) and TUNEL analysis
to estimate apoptosis rates (Supplemental Figure S4B).
ReducingAURKBorWEE1 protein levels led to a statistically
signiﬁcant 47% to 66% decrease in Ki-67epositive tumor cell
proliferation (Figure 5A). In contrast, apoptosis rates of tumor
cells were not signiﬁcantly different between control and
xenografted tumors harvested from animals injected with cells
nucleofected with AURKB siRNA (Figure 5B). A slight
increase in apoptotic tumor cells was observed after knock-
down of WEE1 protein levels as well (Figure 5B). Thus,
decreasing AURKB or WEE1 protein expression levels in
melanoma cells reduced tumor development by decreasing1158cellular proliferation, consistent with these proteins lying
downstream of V600EB-Raf.
Inhibition of AURKB or WEE1 Decreases the Viability of
Cultured Melanoma Cells by Reducing Cellular
Proliferative Potential
To demonstrate that AURKB and WEE1 inhibition reduced
melanoma cell survival by decreasing the proliferative poten-
tial ofmelanomacells, viability byMTSandproliferation using
BrdU incorporation was measured after siRNA-mediated
protein knockdown in cells. Decreasing either AURKB orajp.amjpathol.org - The American Journal of Pathology
Table 1 Effect of Targeting AURKB or WEE1 on Cell Cycle Using FACS Analysis
Variable Buffer siScrambled siB-Raf siAURKB#1 siAURKB#3 siWEE1#2 siWEE1#3
UACC 903
G0/G1 65.7  0.1 65.6  0.2 85.7  2 30.5  0.2 57.5  2.2 31.2  3.0 37.8  0.2
S 26.5  2.9 27.1  2.9 8.2  1 9.6  0.1 17.1  2.4 45.7  5.7 44.0  0.2
G2/M 7.8  3.0 7.3  3.1 6.0  0.9 59.9  0.2 25.3  4.3 23.0  6.5 18.1  1.0
Sub-G0/G1 0.5  1.1 0.4  1.1 0.7  0.1 15.2  0.0 6.0  1.0 7.8  3.6 14.9  0.1
1205 Lu
G0/G1 68.9  1.1 66.6  2.3 70.05  1.0 37.7  0.7 60.4  2.2 35.5  8.2 61.6  7.2
S 20.0  2.2 24.0  4.5 28.78  1.2 10.4  1.6 12.3  2.4 41.1  2.5 13.3  4.4
G2/M 10.2  1.4 9.3  2.6 1.29  0.1 51.9  0.9 27.3  4.3 23.4  5.6 25.0  4.6
Sub-G0/G1 0.5  0.2 0.5  0.2 21.1  0.0 4.0  0.4 3.4  1.0 27.8  4.7 45.1  7.6
A375M
G0/G1 66.28  1.2 69.03  1.0 71.91  0.9 46.26  0.2 50.68  1.3 50.15  0.8 43.28  1.2
S 16.10  0.1 15.44  0.5 13.49  0.5 30.29  1.2 19.19  0.6 22.91  0.9 25.06  3.0
G2/M 16.61  0.3 14.53  0.5 11.60  0.6 24.94  3.0 31.12  0.6 25.44  1.4 29.15  1.8
Sub-G0/G1 2.33  0.3 2.85  0.8 9.13  0.1 23.00  3.0 7.9  0.4 9.14  0.1 22.82  3.8
Data are given as means  SEM percentages, from three to four separate experiments. siRNAs targeting AURKB or WEE1 were introduced into UACC 903,
1205 Lu, or A375M cells, and populations of the cell cycle were analyzed by FACS analysis.
FACS, ﬂuorescence-activated cell sorter.
AURKB and WEE1 Downstream of V600EB-RAFWEE1 reduced melanoma cell growth in UACC 903 and 1205
Lu cells by 50% to 60% (Figure 5C). Decreased survival was
mediated by reduced cellular proliferation because targeting
AURKB or WEE1 led to a 30% to 80% decrease in BrdU
incorporation in both the cell lines (Figure 5D). V600EB-Rafwas
used as the gene control for inhibiting this pathway. Thus,
decreasing AURKB or WEE1 protein levels in cultured
melanoma cells decreased cell survival, mediated by a reduc-
tion in proliferation.
Targeting AURKB or WEE1 Induces a G2/M Block,
Leading to Increased Rates of Cellular Apoptosis
AURKB regulates a crucial spindle checkpoint during cell
division, whose inhibition can cause a premature exit from
mitosis, preventing proper chromosome segregation and cyto-
kinesis, resulting in a G2/M block in the cell cycle.
33,34 WEE1
regulates cell cycle progression by inhibiting entry into mitosis,
and its absence leads to division at a premature stage and
subnormal cell size.20,35 To evaluate the disruption of the cell
cycle mediated by targeting these proteins, cell cycle analysis
using the ﬂuorescence-activated cell sorter was undertaken on
cells after knockdown of AURKB or WEE1 protein levels.
Control UACC 903, 1205 Lu, or A375M cells treated with
buffer or scrambled siRNA had a G2/M cell population of
approximately 7% to 15% compared with cells transfected with
siAURKB having levels ranging from 25% to 60% (Table 1).
Thus, decreasing levels of AURKB or WEE1 protein in
melanoma cells causes an increase in the G2/M population.
AURKB and WEE1 Serve as Indicators of the Therapeutic
Efﬁcacy of Drugs Targeting the MAP Kinase Pathway
To establish whether AURKB or WEE1 could be used as
biomarkers of the efﬁcacy of pharmacological agents targeting
the V600EB-RAFesignaling cascade, the pathway was targetedThe American Journal of Pathology - ajp.amjpathol.orgusing vemurafenib or U0126, known inhibitors of V600EB-Raf
and Mek1/2, respectively.2,9 Treatment of UACC 903 or 1205
Lu with vemurafenib decreased levels of phosphorylated
Mek and Erk (Figure 6A). AURKB and WEE1 protein
expression and/or activity levels decreased with reduction of the
MAP kinaseesignaling cascade after vemurafenib treatment
(Figure 6A) in a manner similar to that of cyclin D1, which is an
established biomarker of proliferation.36 Similarly, treatment
withU0126decreasedpErk1/2 andcyclinD1 levels,whichwere
mirrored by a reduction in AURKB and WEE1 protein and/or
phosphorylation levels (Figure 6A). Tumors in animals treated
with either vemurafenib or U0126 also exhibited decreased
AURKB or WEE1 expression after IHC staining of tumors
treatedwith the drugs comparedwith animals exposed to control
DMSO (Figure 6B and Supplemental Figure S5). Thus,
AURKBandWEE1 levels canbeusedasbiomarkers tomeasure
the therapeutic efﬁcacy of MAP kinase pathway inhibitors.
Demonstration That Pharmacological Inhibition of
Therapeutic Targets Downstream of V600EB-RAF Can
Effectively Inhibit Melanoma Development
To demonstrate the efﬁcacy of a pharmacological agent target-
ingAURKBdownstream in the V600EB-Rafesignaling cascade,
the efﬁcacy of VX-680 (a small-molecule pan-Aurora kinase
inhibitor37), which inhibits cellular proliferation by disrupting
the cell cycle without negatively affecting normal cell survival,
was evaluated.38,39 IC50 values of UACC 903, A375M, and
1205 Lu melanoma cells treated with VX-680 were 8.3, 11.45,
and 8.10 mmol/L, respectively (Supplemental Figure S6A). At
24 hours after drug treatment, melanoma cells were approxi-
mately 3.5- to 5-foldmore sensitive than ﬁbroblasts to the agent.
The drug caused a G2/M block, with the highest accumulation
occurring at 2.5 mmol/L VX-680 (Supplemental Figure S6B).
Higher concentrations led to polyploidization due to continued
cell cycle progression in the absence of cell division, leading to1159
Figure 6 AURKB orWEE1 serve as biomarkers of the activity of pharmacological agents targeting theMAP kinase pathway.A: UACC 903 or 1205 Lu cells were treated
with 0.2 to 20mmol/L vemurafenib, a B-RafV600E inhibitor (left panel), or 2.5 to 50 mmol/L U0126, an MEK1/2 inhibitor (right panel), for 48 hours. Protein lysates were
collected and analyzed for MEK1/2, ERK1/2, cyclin D1, and AURKB or WEE1 expression by using Western blot analysis. a-Enolase served as a control for equal protein
loading. A representative blot from two to three independent experiments is shown.B: Nudemice were injected with 5 106 UACC 903melanoma cells, and 7 days later,
vemurafenib or UO126 treatment at a dose of 10 mg/kg body weight was initiated, once per day for 6 days. Tumors were removed after last treatment and divided into
sections for IHC staining of AURKB or WEE1. The expression of AURKB (top left panel) or WEE1 (top right panel) was quantiﬁed in tumor sections from vemurafenib-
treated animals. Similarly, the expression of AURKB (bottom left panel) or WEE1 (bottom right panel) was quantiﬁed in tumor sections from U0126-treated animals
comparedwithDMSO-treated controls andplotted.Datawere obtained fromthree to four tumors,with four toﬁveﬁelds per tumor analyzed.C: A total of 1 106UACC903
melanoma cells were injected s.c. into the right and leftﬂanks of nudemice, and 6 days later, theywere treated daily i.p. with a dose of 50 or 75mg/kg bodyweight of VX-
680. Developing tumorsweremeasured on alternate days up to day 26 and comparedwith controls treatedwithDMSO. Each point represents data obtained fromﬁve nude
mice (two tumors on each side). Tumor sections were immunostained for AURKB and compared with DMSO controletreated tumors (inset). Data represent three to four
tumors, with four to ﬁve ﬁelds per tumor analyzed.D: Protein lysates were analyzed by usingWestern blot analysis for AURKB, pAURKB, and pHistone-3.a-Enolase served
as a control for equal protein loading. Data represent means SEM. *P< 0.01 (t-test) (B); *P< 0.01, **P< 0.001, analysis of variance, followed by a post hoc test (C).
Sharma et alaG0/G1 block; hence, fewer cells were observed inG2/M than at
lower concentrations, which would eventually lead to disap-
pearance of the G2/M population.
40 The i.p. administration of
VX-680 at 50 and 75 mg/kg body weight reduced melanoma
tumor development by 78% compared with DMSO control-
treated mice and decreased AURKB expression in tumor cells
measured by IHC (Figure 6C). In addition, decreased expression
and activity ofAURKB, asmeasuredbypHistone-3 levels,were
observed in VX-680etreated tumors harvested at day 26
(Figure 6D). Thus, pharmacological inhibition of AURKB
decreased melanoma cell proliferation by inducing a G2/M
block, which reduced melanoma tumor development.
Discussion
BRAF is the most mutated gene in melanoma constitutively
activating the MAP kinaseesignaling cascade.7 Vemurafenib
preferentially binds toV600EB-Raf to inactivate thepathway.11,41
Although the drug is initially effective at reducing the tumor1160burden of patients, resistance quickly develops in the initial
responders, leading to disease progression and death.17,42
Therefore, new and novel approaches are needed to overcome
this drug-induced resistance. One approach could be to target
proteins downstream in the V600EB-RAF signaling cascade.
This report identiﬁes AURKB and WEE1 as two kinases
lying downstream of V600EB-RAF in the MAP kinasee
signaling cascade, which can be used as therapeutic targets or
biomarkers of drug efﬁcacy for agents inhibiting this pathway.
A series of siRNA-based screens were undertaken using
a library of 636 kinases, which identiﬁed AURKB, WEE1,
GSK3A, TPK1, and B-RAF as potential modulators of mela-
noma cell survival. However, onlyAURKBandWEE1protein
levels decreasedwhenV600EB-RAF,MEK1/2, orERK1/2were
targeted using siRNA, demonstrating that these proteins were
downstream in this signaling cascade.
AURKB and WEE1 protein levels were increased in
tumors of patients with melanoma and in cell lines with
highest amounts found in those derived from advancedajp.amjpathol.org - The American Journal of Pathology
AURKB and WEE1 Downstream of V600EB-RAFdisease, thereby further validating the potential importance of
these proteins in melanoma development. In accordance with
our results, Magnussen et al43 recently reported up-regulation
of WEE1 in human malignant melanomas compared with
benign nevi, and normal melanocyteeincreased expression
also occurs in breast cancer and glioblastoma.44,45 Studies in
this report have demonstrated that siRNA-mediated reduction
of AURKB or WEE1 expression in melanoma cells reduced
tumor development by 80% to 90% compared with controls,
which showed that these downstreamMAP kinaseesignaling
proteins could be potentially important therapeutic targets.
Reducing AURKB or WEE1 protein levels led to a statisti-
cally signiﬁcant 47% to66%decrease inKi-67epositive tumor
cells, which is a phenotype similar to that observed when
inhibiting V600EB-RAF.10 Fluorescence-activated cell sorter
analysis of cells after knockdown ofAURKBorWEE1protein
levels led to an increase in the G2/M population, which
ultimately increased apoptotic cell death. AURKB is a chro-
mosomal passenger protein regulating early mitotic stage
transition of prophase tometaphase.46,47 Inhibition ofAURKB
has been reported to halt a crucial spindle checkpoint causing
premature exit from mitosis-disrupting chromosome segrega-
tion and cytokinesis, which occurred in this study when the
gene was targeted.47WEE1 regulates cell cycle progression by
phosphorylating and deactivating cyclin-associatedCDK1 and
CDK2 at Tyr15.20 Inhibition of tumor cell proliferation and
induction of apoptosis have been reported by targeting WEE1
using siRNA or small-molecule inhibitors either alone or in
combination with DNA damaging agents for several malig-
nancies,20,48 and small molecule WEE1 inhibitors are being
evaluated in phase I clinical trials.20
Pharmacological agents can inhibit these proteins to target
melanoma development. Targeting AURKB using VX-680,
which is a small molecule pan-Aurora kinase inhibitor,
decreased melanoma tumor development by 78% compared to
controls. The drug inhibited cell proliferation by disrupting the
cell cycle causing a G2/M block and increasing apoptosis rates.
Inhibition of WEE1 with PD0166285 or siRNA to reduce
WEE1 protein levels and combined with irradiation decreased
the G2/M cell population and triggered apoptosis.
19,49
This is also the ﬁrst study to show that AURKB andWEE1
can serve as biomarkers of the therapeutic efﬁcacy of drugs
targeting the MAP kinase pathway. Treatment of melanoma
cells in culture or in animals with vemurafenib or U0126
decreased levels of phosphorylated Mek and Erk and down-
stream AURKB or WEE1 expression and/or activity levels.
For these studies, cyclin D1 served as a control because it is
commonly used as an indicator of cellular proliferation.50
Levels of AURKB and WEE1 were decreased in a manner
similar to that observed for cyclin D1, indicating that these
proteins could be used in a likewise manner. Thus, AURKB
and WEE1 levels can be used as biomarkers to measure the
therapeutic efﬁcacy of MAP kinase pathway inhibitors.
Targeting AURKB or WEE1 using siRNA decreased
cellular proliferation, inducing a G2/M block, and increased the
apoptotic sub-G0/G1 cell population, which signiﬁcantlyThe American Journal of Pathology - ajp.amjpathol.orgdecreased tumor development. Consistent with these observa-
tions, several reports in the literature document that WEE1 or
AURKB inhibition using siRNA or pharmacological agents,
combined with DNA-damaging therapy (either irradiation or
cytostatic agents), can effectively decrease cellular proliferation
and induce apoptosis by triggering mitotic catastrophe.51,52
In conclusion,WEE1 andAURKB are potentially important
therapeutic targets downstream of V600EB-Raf in the MAP
kinase signaling cascade. These proteins could be inhibited
alone or in combination with B-RAFetargeting agents to more
effectively treat patients having the V600E mutation or over-
come resistance encountered when treating patients with
inhibitors of this pathway. Furthermore, WEE1 or AURKB
could be used as biomarkers to assess the efﬁcacy of agents
targeting the deregulated MAP kinase pathway in melanomas.
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